FacultyFaculty/Author Profile
Keith A. Zullow

Keith A. Zullow

Goodwin Procter LLP

New York, NY, USA


Keith Zullow, a partner in Goodwin's IP Litigation Group, is a U.S. registered patent attorney with significant trial experience in chemical and pharmaceutical patent litigation. He is also experienced in interference practice and trade secret litigation. Mr. Zullow has worked on cases in various federal district courts throughout the United States, on appeals before the U.S. Court of Appeals for the Federal Circuit and other circuit courts, and is lead counsel on proceedings before the Patent Trial and Appeal Board.

Experience

In recent years, Mr. Zullow has served as trial counsel in pharmaceutical patent litigation for companies including Roxane Laboratories and Teva Pharmaceuticals USA. Some of his recent engagements include the following:

  • Lead trial counsel for Roxane in a series of patent infringement actions filed by Novartis relating to Roxane’s filing of abbreviated new drug applications for generic versions of Novartis’s drugs ZORTRESS® and AFINITOR®. Lead counsel on Inter Partes Reviews relating to two of the patents-in-suit. A first trial was held in August 2015 and a decision is pending. A second trial is scheduled for May 2017.
  • Co-lead counsel for Teva in a patent infringement action filed by Otsuka under the Hatch Waxman Act relating to Teva’s filing of abbreviated new drug applications for generic versions of Otsuka’s drug ABILIFY®. Teva defeated a motion for a temporary restraining order which allowed Teva to launch its products. The case against Teva successfully settled before trial.

Other recent engagements include the following:

  • Lead trial counsel for Roxane in a patent infringement action filed by Prometheus Laboratories under the Hatch Waxman Act in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’ drug LOTRONEX®. After a bench trial, the District Court found Prometheus’s patent invalid. The finding of invalidity was affirmed by the Federal Circuit.
  • Co-lead counsel for Teva in a patent infringement action filed by Pfizer relating to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Pfizer’s drug CELEBREX®. The District Court found Pfizer’s patent invalid on summary judgment. The finding of invalidity was affirmed by the Federal Circuit.
  • Co-lead trial counsel for Roxane in a patent infringement action filed by Genzyme under the Hatch Waxman Act in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s drug HECTEROL®. The case successfully settled after trial.
  • Co-lead trial counsel for Teva in a patent infringement action filed by Pfizer under the Hatch Waxman Act relating to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Pfizer’s drug VIAGRA®. The case successfully settled after trial.
  • Co-lead counsel for Teva in a patent infringement action filed by AstraZeneca under the Hatch Waxman Act relating to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of AstraZeneca’s drug PULMICORT RESPULES®. The case successfully settled before trial.

Professional Experience

Before joining Goodwin, Mr. Zullow was an associate at Fish & Neave, where his work focused on intellectual property litigation, trade secret litigation, interference practice and patent prosecution for clients including ExxonMobil Chemical Company, Hoechst Celanese, Aventis Pharmaceuticals, The Gillette Company and Phelps Dodge.

Viewpoints

Mr. Zullow published a series of articles examining patent issues related to plants and seeds in Cereal Foods World, which included:

  • “Protecting Intellectual Property in Plants and Seeds,” Cereal Foods World (November 2008)
  • “Enforcing Patents,” Cereal Foods World (October 2008)
  • “The Anatomy of a Patent,” Cereal Foods World (August 2008)
  • “Obtaining a Patent,” Cereal Foods World (June 2008)
  • “The Interplay Between Patents and Other Forms of Intellectual Property,” Cereal Foods World (March 2008)
  • “Introduction to the United States Patent Systems,” Cereal Foods World (January 2008)

Education

  • J.D., New York University School of Law, 1994
  • B.S., Chemical Engineering, Cornell University, 1987 (with distinction)

Admissions

Mr. Zullow is admitted to practice in New York, as well as before the U.S. Supreme Court, the U.S. Court of Appeals for the Federal Circuit, and the U.S. District Courts for the Southern and Eastern Districts of New York. He is also admitted to practice before the U.S. Patent and Trademark Office.

Keith A. Zullow is associated with the following items:
Live Seminar  Live Seminar Understanding Patent Law 2018, Thursday, May 24, 2018, New York, NY
Live Webcast  Live Webcast Understanding Patent Law 2018, Thursday, May 24, 2018, New York, NY
PLI Grpcast-Live Web  PLI Grpcast-Live Web Understanding Patent Law 2018, Thursday, May 24, 2018, New Brunswick , NJ
Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • GooglePlus
  • RSS

All Contents Copyright © 1996-2018 Practising Law Institute. Continuing Legal Education since 1933.

© 2018 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.